Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Phase I, Dose Escalation Study of Decitabine

    ... (CR) following allo-HSCT ( bone marrow leukemic blasts less than 5% by morphology ), with high risk features ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  2. Allo HSCT Using RIC for Hematological Diseases

    ... be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a ... <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  3. Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

    ... adult patients with pathologically confirmed MDS (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 05/03/2016 - 9:46am.

  4. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... or morphologic complete remission or MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating ...

    Clinical Trial last updated 05/02/2016 - 11:06am.

  5. Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

    ... based solely on the percentage of bone marrow blasts , cytogenetics (branch of genetics which studies the ...

    Research Review last updated 05/02/2016 - 9:31am.

  6. Clofarabine in the treatment of myelodysplastic syndromes

    ... DNA synthesis and can reduce the percentage of leukemic blasts in adult patients with MDS and acute myeloid leukemia (AML).  Early ...

    Research Review last updated 05/02/2016 - 9:18am.

  7. Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

    ... confirmed Myelodysplastic Syndrome, or MDS, (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 04/29/2016 - 1:36pm.

  8. A Combination Study of PF-04449913 and Azacitidine In 1st Line MDS, AML and CMML Patients

    ... (MDS), Acute Myeloid Leukemia (AML) with 20-30% blasts and multi lineage dysplasia, and Chronic Myelomonocytic Leukemia ...

    Clinical Trial last updated 04/27/2016 - 1:20pm.

  9. Lower-Risk MDS: Diagnosis and Treatment Options

    ... 100,000/mm3. The second criterion is the percentage of blasts , or immature white blood cells in the bone marrow , ... is the World Health Organization (WHO) classification, 20% blasts or greater establishes a diagnosis of acute myeloid leukemia, rather ...

    Interview last updated 05/18/2012 - 1:28pm.

  10. Clone of Myelodysplastic Syndromes (MDS)

    ... Blast Counts Blasts are very young or immature white blood cells. In normal bone marrow , no more than 5 out of 100 white cells are blasts. Because people with MDS may have too many bone marrow blasts, doctors ...

    Page last updated 04/05/2016 - 3:56pm.